Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Enrico Premi
University of Brescia
82Publications
17H-index
1,005Citations
Publications 82
Newest
Published on May 1, 2019in Neurobiology of Aging 4.45
Timothy Rittman18
Estimated H-index: 18
(University of Cambridge),
Robin Borchert4
Estimated H-index: 4
(University of Cambridge)
+ 122 AuthorsFabrizio Tagliavini60
Estimated H-index: 60
The presymptomatic phase of neurodegenerative diseases are characterized by structural brain changes without significant clinical features. We set out to investigate the contribution of functional network resilience to preserved cognition in presymptomatic genetic frontotemporal dementia. We studied 172 people from families carrying genetic abnormalities in C9orf72, MAPT, or PGRN. Networks were extracted from functional MRI data and assessed using graph theoretical analysis. We found that despit...
Source Cite
Published on Apr 1, 2019in NeuroImage 5.43
Enrico Premi17
Estimated H-index: 17
(University of Brescia),
Vince Daniel Calhoun87
Estimated H-index: 87
(UNM: University of New Mexico)
+ 130 AuthorsJohn VanSwieten68
Estimated H-index: 68
(EUR: Erasmus University Rotterdam)
Abstract Frontotemporal Dementia (FTD) is preceded by a long period of subtle brain changes, occurring in the absence of overt cognitive symptoms, that need to be still fully characterized. Dynamic network analysis based on resting-state magnetic resonance imaging (rs-fMRI) is a potentially powerful tool for the study of preclinical FTD. In the present study, we employed a "chronnectome" approach (recurring, time-varying patterns of connectivity) to evaluate measures of dynamic connectivity in 4...
Source Cite
Published on Apr 1, 2019in Neurobiology of Aging 4.45
Alberto Benussi10
Estimated H-index: 10
(University of Brescia),
Stefano Gazzina9
Estimated H-index: 9
(University of Brescia)
+ 11 AuthorsAnna Micheli5
Estimated H-index: 5
Abstract Presymptomatic carriers of GRN and C9orf72 mutations, the most frequent genetic causes of frontotemporal lobar degeneration, represent the optimal target population for the development of disease-modifying drugs. Preclinical biomarkers are needed to monitor the effect of therapeutic interventions in this population. We assessed clinical, functional, and neurophysiological measures in 113 GRN or C9orf72 carriers and in 73 noncarrier first-degree relatives. For 73 patients, follow-up long...
1 Citations Source Cite
Published on Mar 14, 2019in Frontiers in Neuroscience 3.88
Valentina Saba (UNIPV: University of Pavia), Enrico Premi17
Estimated H-index: 17
(University of Brescia)
+ 7 AuthorsMario Grassi29
Estimated H-index: 29
(UNIPV: University of Pavia)
Brain functional disruption and cognitive shortfalls as consequences of neurodegeneration are among the most investigated aspects in current clinical research. Traditionally, specific anatomical and behavioural traits have been associated with neurodegeneration, thus directly translatable in clinical terms. However, these qualitative traits, do not account for the extensive information flow breakdown within the functional brain network that deeply affect cognitive skills. Behavioural variant Fro...
Source Cite
Published on Mar 1, 2019in Parkinsonism & Related Disorders 4.72
Marta Manes4
Estimated H-index: 4
(University of Brescia),
Antonella Alberici26
Estimated H-index: 26
(University of Brescia)
+ 14 AuthorsLaura Orsi14
Estimated H-index: 14
Abstract Introduction Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. Methods Nine SCA38 patients underwent standardised clinical assessment at 62 (T1), 82 (T2) and 104 (T3) weeks, and compared to pre...
Source Cite
Published on Mar 1, 2019in NeuroImage 5.43
Claire Cury1
Estimated H-index: 1
(UCL: University College London),
Stanley Durrleman18
Estimated H-index: 18
(University of Paris)
+ 61 AuthorsMario Masellis36
Estimated H-index: 36
(Sunnybrook Health Sciences Centre)
Brain atrophy as measured from structural MR images, is one of the primary imaging biomarkers used to track neurodegenerative disease progression. In diseases such as frontotemporal dementia or Alzheimer's disease, atrophy can be observed in key brain structures years before any clinical symptoms are present. Atrophy is most commonly captured as volume change of key structures and the shape changes of these structures are typically not analysed despite being potentially more sensitive than summa...
1 Citations Source Cite
Published on Jan 31, 2019in bioRxiv
Franco Cauda27
Estimated H-index: 27
(UNITO: University of Turin),
Andrea Nani6
Estimated H-index: 6
(UNITO: University of Turin)
+ 5 AuthorsTommaso Costa14
Estimated H-index: 14
(UNITO: University of Turin)
In the field of neuroimaging reverse inferences can lead us to suppose the involvement of cognitive processes from certain patterns of brain activity. Still, the same reasoning holds if we substitute 9brain activity9 with 9brain alteration9 and 9cognitive process9 with 9brain disorder9. To assess the involvement of a certain alteration pattern in a brain disorder we used the Bayes9 factor technique on voxel-based morphometry data of schizophrenia and Alzheimer9s disease. This technique allows to...
Source Cite
123456789